Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 6/2016

Open Access 01-06-2016 | Mini-review

Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions

Author: Kenneth Cusi

Published in: Diabetologia | Issue 6/2016

Login to get access

Abstract

Non-alcoholic fatty liver disease (NAFLD) is reaching epidemic proportions in patients with type 2 diabetes. Patients with NAFLD are at increased risk of more aggressive liver disease (non-alcoholic steatohepatitis [NASH]) and at a higher risk of death from cirrhosis, hepatocellular carcinoma and cardiovascular disease. Dysfunctional adipose tissue and insulin resistance play an important role in the pathogenesis of NASH, creating the conditions for hepatocyte lipotoxicity. Mitochondrial defects are at the core of the paradigm linking chronic excess substrate supply, insulin resistance and NASH. Recent work indicates that patients with NASH have more severe insulin resistance and lipotoxicity compared with matched obese controls with only isolated steatosis. This review focuses on available agents and future drugs under development for the treatment of NAFLD/NASH in type 2 diabetes. Reversal of lipotoxicity with pioglitazone is associated with significant histological improvement, which occurs within 6 months and persists with continued treatment (or for at least 3 years) in patients with prediabetes or type 2 diabetes, holding potential to modify the natural history of the disease. These results also suggest that pioglitazone may become the standard of care for this population. Benefit has also been reported in non-diabetic patients. Recent promising results with glucagon-like peptide 1 receptor agonists have opened another new treatment avenue for NASH. Many agents in Phase 2-3 of development are being tested, aiming to restore glucose/lipid metabolism, ameliorate adipose tissue and liver inflammation, or to inhibit liver fibrosis. By targeting a diversity of relevant pathways, combination therapy in NASH will likely provide greater success in the future. In summary, increased clinical awareness and improved screening strategies (as currently done for diabetic retinopathy and nephropathy) are needed, to translate recent treatment progress into early treatment and improved quality of life for patients with type 2 diabetes and NASH. This review summarises a presentation given at the symposium ‘The liver in focus’ at the 2015 annual meeting of the EASD. It is accompanied by two other reviews on topics from this symposium (by John Jones, DOI: 10.​1007/​s00125-016-3940-5, and by Hannele Yki-Järvinen, DOI: 10.​1007/​s00125-016-3944-1) and a commentary by the Session Chair, Michael Roden (DOI: 10.​1007/​s00125-016-3911-x).
Literature
1.
Cusi K (2012) Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 142:711–725CrossRefPubMed
2.
3.
Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment and outcomes. Clin Gastroenterol Hepatol 13:2062-2070
4.
Armstrong MJ, Adams LA, Canbay A, Syn W-K (2014) Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59:1174–1197
5.
Lomonaco R, Ortiz-Lopez C, Orsak B et al (2011) Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology 54:837–845CrossRefPubMed
6.
Maximos M, Bril F, Portillo-Sanchez P et al (2015) The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology 61:153–160CrossRefPubMed
7.
Bril F, Ortiz-Lopez C, Lomonaco R et al (2015) Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int 35:2139–2146CrossRefPubMed
8.
Portillo-Sanchez P, Bril F, Maximos M et al (2015) High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab 100:2231–2238CrossRefPubMed
9.
Targher G, Bertolini L, Padovani R et al (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:1212–1218CrossRefPubMed
10.
Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR (2009) Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 29:113–119CrossRefPubMed
11.
Leite NC, Villela-Nogueira CA, Pannain VL et al (2011) Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int 31:700–706CrossRefPubMed
12.
Casey SP, Kemp WW, McLean CA, Topliss DJ, Adams LA, Roberts SK (2012) A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease. Scand J Gastroenterol 47:836–841CrossRefPubMed
13.
Kwok R, Choi KC, Wong GL et al (2015) Screening diabetic patients for nonalcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. doi:10.​1136/​gutjnl-2015-309265 PubMed
14.
Koehler EM, Plompen EP, Schouten JN, Hansen BE, Darwish Murad S, Taimr P et al (2016) Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology 63:138–147CrossRefPubMed
15.
Pais R, Charlotte F, Fedchuk L et al (2013) A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 59:550–556CrossRefPubMed
16.
Ekstedt M, Hagstrom H, Nasr P et al (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61:1547–1554CrossRefPubMed
17.
Angulo P, Kleiner DE, Dam-Larsen S et al (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149:389.e310–397.e310CrossRef
18.
Raff EJ, Kakati D, Bloomer JR, Shoreibah M, Rasheed K, Singal AK (2015) Diabetes mellitus predicts occurrence of cirrhosis an hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases. J Clin Transl Hepatol 3:9–16CrossRefPubMedPubMedCentral
19.
Younossi Z, Otgonsuren M, Henry L et al (2015) Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62:1723–1730CrossRefPubMed
20.
Rinella ME, Lominadze Z, Loomba R et al (2016) Practice patterns in NAFLD and NASH: real life differs from published guidelines. Ther Adv Gastroenterol 9:4–12CrossRef
21.
Wong RJ, Aguilar M, Cheung R et al (2015) Nonalcoholic steatohepatitis is the second leading etiology of liver diseaseamong adults awaiting liver transplantation in the United States. Gastroenterology 48:547–555CrossRef
22.
23.
Bril F, Sninsky JJ, Baca AM et al (2016) Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD. J Clin Endocrinol Metab 101:644–652
24.
Bril F, Lomonaco R, Orsak B et al (2015) Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology 59:2178–2187CrossRef
25.
Ahmed A, Perumpail RB, Harrison SA (2016) High prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: a case for selective screening in the general population? Hepatology 63:20–22CrossRefPubMed
26.
Chalasani N, Younossi Z, Lavine JE et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Gastroenterology 142:1592–1609CrossRefPubMed
27.
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) (2016) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. doi:10.​1007/​s00125-016-3902-y
28.
Lomonaco R, Sunny NE, Bril F, Cusi K (2013) Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 73:1–14CrossRefPubMed
29.
Bugianesi E, Gentilcore E, Manini R et al (2005) A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100:1082–1090CrossRefPubMed
30.
Loomba R, Lutchman G, Kleiner DE et al (2009) Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 29:172–182CrossRefPubMedPubMedCentral
31.
Lavine JE, Schwimmer JB, Van Natta ML et al (2011) Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305:1659–1668CrossRefPubMedPubMedCentral
32.
Lomonaco R, Bril F, Portillo-Sanchez P et al (2016) Metabolic impact of nonalcoholic steatohepatitis (NASH) in obese patients with type 2 diabetes mellitus. Diabetes Care. doi:10.​2337/​dc15-1876 PubMed
33.
Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B (2013) Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 58:1497–1507CrossRefPubMed
34.
Sunny NE, Kalavalapalli S, Bril F et al (2015) Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab 309:E311–E319CrossRefPubMed
35.
36.
Perry RJ, Zhang D, Zhang XM, Boyer JL, Shulman GI (2015) Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. Science 347:1253–1256CrossRefPubMedPubMedCentral
37.
Satapati S, Kucejova B, Duarte JA et al (2015) Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J Clin Invest 125:4447–4462CrossRefPubMed
38.
Koliaki C, Szendroedi J, Jelenik T et al (2015) Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver or steatohepatitis. Cell Metab 21:739–746CrossRefPubMed
39.
Sunny NE, Parks EJ, Browning JD, Burgess SC (2011) Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 14:804–810CrossRefPubMedPubMedCentral
40.
Finan B, Yang B, Ottaway N et al (2015) A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21:27–36CrossRefPubMed
41.
42.
Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297–2307CrossRefPubMed
43.
Gastaldelli A, Harrison S, Belfort R et al (2009) Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50:1087–1093CrossRefPubMed
44.
Gastaldelli A, Harrison S, Belfort-Aguiar R et al (2010) Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther 32:769–775CrossRefPubMed
45.
Bril F, Portillo Sanchez P, Maximos M et al (2015) Metabolic predictors of response to pioglitazone treatment in patients with prediabetes or type 2 diabetes mellitus and nonalcoholic steatohepatitis. Diabetes 64:A337 (Abstract)
46.
DeFronzo RA, Tripathy D, Schwenke DC et al (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364:1104–1115CrossRefPubMed
47.
Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S (2013) Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol 108:1861–1868CrossRefPubMed
48.
Aithal GP, Thomas JA, Kaye PV et al (2008) Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135:1176–1184CrossRefPubMed
49.
50.
Berria R, Gastaldelli A, Lucidi S et al (2006) Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clin Pharmacol Ther 80:105–114
51.
Balas B, Belfort R, Harrison S et al (2007) Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol 47:565–570CrossRefPubMed
52.
VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA (2015) Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology 62:773–783CrossRefPubMed
53.
Yau H, Rivera K, Lomonaco R, Cusi K (2013) The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep 13:329–341CrossRefPubMed
54.
Lewis JD, Habel LA, Quesenberry CP et al (2015) Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314:265–277CrossRefPubMed
55.
Portillo-Sanchez P, Cusi K (2016) Treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus. Clin Diab Endocrinol (in press)
56.
Armstrong MJ, Houlihan DD, Rowe IA et al (2013) Safety and efficacy of liraglutide in patients with type 2 diabetes with elevated liver enzymes: individual patient data meta-analysis of the LEAD programme. Aliment Pharmacol Ther 37:234–242CrossRefPubMed
57.
Armstrong MJ, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387:679–690CrossRefPubMed
58.
Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL (2016) Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatophepatitis. J Hepatol 64:399–408CrossRefPubMedPubMedCentral
59.
Portillo P, Yavuz S, Bril F, Cusi K (2014) Role of insulin resistance and diabetes in the pathogenesis and treatment of nonalcoholic fatty liver disease. Curr Hepatol Rep 13:159–170CrossRef
60.
Gupta NA, Mells J, Dunham RM et al (2010) Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51:1584–1592CrossRefPubMedPubMedCentral
61.
Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C (2011) Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 31:1285–1297CrossRefPubMed
62.
Iwasaki T, Yoneda M, Inamori M et al (2011) Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology 58:2103–2105CrossRefPubMed
63.
Fukuhara T, Hyogo H, Ochi H et al (2014) Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology 61:323–328PubMed
64.
65.
Mudaliar S, Polidori D, Zambrowicz B, Henry RR (2015) Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 38:2344–2353CrossRefPubMed
66.
Hayashizaki-Someya Y, Kurosaki E, Takasu T et al (2015) Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol 754:19–24CrossRefPubMed
67.
Lavalle-Gonzalez FJ, Januszewicz A, Davidson J et al (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56:2582–2592CrossRefPubMedPubMedCentral
68.
Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375:2223–2233CrossRefPubMed
69.
Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S (2016) Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 42:25–32CrossRefPubMed
70.
Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA (2009) A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 43:990–994CrossRefPubMed
71.
Loomba R, Sirlin CB, Ang B et al (2015) Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 61:1239–1250CrossRefPubMedPubMedCentral
72.
Fabbrini E, Mohammed BS, Korenblat KM et al (2010) Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 95:2727–2735CrossRefPubMedPubMedCentral
73.
Dasarathy S, Dasarathy J, Khiyami A et al (2015) Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 49:137–144CrossRefPubMedPubMedCentral
74.
Le TA, Chen J, Changchien C et al (2012) Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 56:922–932CrossRefPubMedPubMedCentral
75.
Klein EA, Thompson IM, Tangen CM et al (2011) Vitamin E and the risk of prostate cancer: updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306:1549–1556CrossRefPubMedPubMedCentral
76.
Van Wagner LB, Koppe SW, Brunt EM et al (2011) Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 10:277–286PubMed
77.
Zein CO, Yerian LM, Gogate P et al (2011) Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 54:1610–1619CrossRefPubMedPubMedCentral
78.
Stefan N, Ramsauer M, Jordan P et al (2014) Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2:406–416CrossRefPubMed
79.
Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T (2014) The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12:2085–2091CrossRefPubMed
80.
Cariou B, Staels B (2014) GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. Expert Opin Investig Drugs 23:1441–1448CrossRefPubMed
81.
Staels B, Rubenstrunk A, Noel B et al (2013) Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 58:1941–1952CrossRefPubMed
82.
Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A et al (2008) Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance. Cell Metab 7:496–507
83.
Cariou B, Hanf R, Lambert-Porcheron S et al (2013) Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 36:2923–2930CrossRefPubMedPubMedCentral
84.
Belfort R, Berria R, Cornell J, Cusi K (2010) Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 95:829–836CrossRefPubMedPubMedCentral
85.
Ratziu V, Harrison S, Francque SM et al (2016) Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of non-alcoholic steatohepatitis without fibrosis worsening. Gastroenterology. doi:10.​1053/​j.​gastro.​2016.​01.​038 PubMed
86.
Lefebvre E, Hashiguchi T, Jenkins H et al (2013) Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH. Hepatology 58(S1):221A–222A (Abstract)
87.
Krenkel O, Püngel T, Mossanen JC et al (2015) Dual CCR2 and CCR5 antagonist cenicriviroc leads to potent and significant reduction in proinflammatory CCR2+ monocyte infiltration in experimental acute liver injury. Hepatology 62(S1):1065 (Abstract no. 1756)
88.
Friedman S, Sanyal A, Goodman Z et al (2016) Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemp Clin Trials 47:356–365CrossRefPubMed
89.
90.
Fisher FM, Chui PC, Nasser IA et al (2014) Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 147:1073–1083CrossRefPubMedPubMedCentral
91.
92.
Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al (2015) Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385:956–965CrossRefPubMedPubMedCentral
93.
Mudaliar S, Henry RR, Sanyal AJ et al (2013) Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145:574–582CrossRefPubMed
94.
Neuschwander-Tetri BA (2010) Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52:774–788CrossRefPubMed
95.
Metadata
Title
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions
Author
Kenneth Cusi
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 6/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-3952-1

Other articles of this Issue 6/2016

Diabetologia 6/2016 Go to the issue

Article

PGE2 receptor EP3 inhibits water reabsorption and contributes to polyuria and kidney injury in a streptozotocin-induced mouse model of diabetes

Commentary

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action?

Article

Transcriptional networks of murine diabetic peripheral neuropathy and nephropathy: common and distinct gene expression patterns

Article

Recent trends in life expectancy for people with type 1 diabetes in Sweden

Article

Egg consumption and risk of type 2 diabetes: a prospective study and dose–response meta-analysis

Short Communication

Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits